Every 2.8 seconds someone dies from sepsis.
Sepsis is a life-threatening condition associated with Galectin-3, a protein involved in the inflammatory response. Eliaz Therapeutics' patented investigational technology, XGal-3®, is designed to remove Galectin-3 directly from the bloodstream.
learn more
Worldwide Impact of Sepsis
7.5%
US in-patient share
4-9%
Mortality ↑ per hour
$36.4K
Cost per patient
350K
US deaths / year
48.9M
Global cases / year
11.0M
Global deaths / year
1.7M
US hospitalizations
7.5%
US in-patient share
4-9%
Mortality ↑ per hour
$36.4K
Cost per patient
350K
US deaths / year
48.9M
Global cases / year
11.0M
Global deaths / year
1.7M
US hospitalizations
7.5%
US in-patient share
4-9%
Mortality ↑ per hour
$36.4K
Cost per patient
350K
US deaths / year
48.9M
Global cases / year
11.0M
Global deaths / year
1.7M
US hospitalizations
a Root Cause
of Disease
A key protein driving sepsis, cancer, heart disease, fibrosis, and kidney disease.
How Eliaz Therapeutics
Approaches this Root Cause
A Central Driver of Disease, Inflammation, and Fibrosis
Galectin-3 regulates immune response, inflammation, and tissue repair in response to stress and injury.
When Your Body’s Protection Turns Harmful
Elevated Galectin-3 shifts from a protective role to a driver of inflammation, contributing to life-threatening conditions Comment start such as Comment end sepsis, kidney disease, fibrosis, and cancer progression.
A Validated Target with No Approved Treatment Yet
Supported by 10,000+ studies, yet no approved treatment exists to remove Galectin-3.
The XGAL-3® device
Targeted Removal
Designed to selectively remove Galectin-3
Therapeutic Apheresis
Blood is processed outside the body and returned to circulation
Proprietary Resin
Antibody-based resin engineered to bind Galectin-3
About Eliaz Therapeutics
Solid Foundation
learn more
FDA Breakthrough Device Designation Award
Awarded by the FDA to innovations expected to offer more effective treatment for serious or life-threatening diseases.
Preclinical Proof + Operational Readiness
Published, peer-reviewed research with data demonstrating improved organ function and reduced mortality in animal models. Product prototype and first-in-human clinical studies ready for validation.
National Institutes of Health Funding
Awarded $1.9M in funding from the NIH for large-animal safety studies and additional R&D support.
Global IP Portfolio Protection
Global protection for our platform technology and therapeutic method.
learn more
